Skip to content
Buy This GLP
← Research
Evidence

Is It Safe to Take a GLP-1 Long Term? What Four Years of Trials Show

Semaglutide and tirzepatide trials tracked outcomes for years. This guide covers common side effects and FDA’s November 2026 warning about a rare eye condition.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team7 min read

Long-term evidence depends on the medicine, the condition and the patient. SELECT followed adults with cardiovascular disease and without diabetes. Its follow-up analysis found lower rates of serious adverse events in the semaglutide group across the starting BMI categories studied [1]. In the primary trial, 33.4% of participants on semaglutide and 36.4% on placebo reported serious adverse events [7]. A separate FDA analysis detected a possible increase in a rare eye condition across GLP-1 trials [6].

Four years of semaglutide: SELECT

SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, none with diabetes. A major cardiovascular event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group (hazard ratio 0.80, 95% CI 0.72 to 0.90) [7]. A prespecified analysis then looked at weight and safety by starting BMI.

At 208 weeks, weight was down 10.2% on semaglutide against 1.5% on placebo. Serious adverse events ran lower on semaglutide in every BMI group. Per 100 years of observation, the rates were 43.23, 43.54, 51.07 and 47.06 on semaglutide. On placebo they were 50.48, 49.66, 52.73 and 60.85 [1].

Adverse events led to permanent discontinuation in 16.6% of the semaglutide group and 8.2% of the placebo group. In the semaglutide group, that rate rose as starting BMI fell[1].

Two years: STEP 5

STEP 5 randomized 304 adults to semaglutide 2.4 mg or placebo for 104 weeks [2]. Mean weight fell by 15.2% on semaglutide and 2.6% on placebo. The trial completion rate was 92.8%.

Gastrointestinal adverse events were reported by 82.2% on semaglutide and 53.9% on placebo. Most were mild to moderate [2]. The side-effect guide explains how common symptoms vary during dose escalation.

A meta-analysis pooled four trials of at least 68 weeks, with 3,087 participants [3]. The risk of gastrointestinal events was higher on semaglutide, a relative risk of 1.47 (95% CI 1.28 to 1.68). The authors add that most were transient, mild to moderate, and did not require stopping treatment.

Three and a half years of tirzepatide: SURMOUNT-1

SURMOUNT-1 followed 1,032 adults with obesity and prediabetes on tirzepatide 5, 10 or 15 mg or placebo for 176 weeks, then 17 weeks off [4]. Weight was down 12.3%, 18.7% and 19.7% by dose, against 1.3% on placebo [4].

On safety, the most common adverse events other than COVID-19 were gastrointestinal. Most were mild to moderate, and they occurred mainly during dose escalation in the first 20 weeks. The authors reported no new safety signals over the three years [4].

The warning that no trial has settled

The Wegovy label for semaglutide carries a boxed warning on thyroid C-cell tumors [5]. In rodents, semaglutide causes them, dependent on dose and treatment duration. Whether it does so in humans is unknown, because the label states that human relevance has not been determined.

The label’s rule is a condition, not a probability. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, or with MEN 2. Four years of trial follow-up does not resolve a question framed in those terms.

FDA’s November 2026 warning about a rare eye condition

On November 9, FDA required a warning about a possible increased risk of nonarteritic anterior ischemic optic neuropathy (NAION) for GLP-1 medicines. NAION can cause sudden, painless loss of vision, usually in one eye. FDA found 10 probable cases in GLP-1 groups and five in comparator groups across 126 trials. That was 6.4 versus 3.8 cases per 100,000 person-years [6].

The pooled figures span several medicines and do not measure a particular person’s risk. FDA advises people to report sudden vision loss or other new vision changes in one eye immediately [6].

What the trials do not answer

These trials give limited information beyond their follow-up periods or for people who would not have qualified. Trials that tracked weight regain after stopping treatment measured what happened after withdrawal. The maintenance-dose guide covers a trial that compared two continued tirzepatide doses with switching to placebo.

A review of real-world studies in people with obesity and without diabetes found that about a third were still taking them at one year [8].

What long term costs

A benefit that depends on continued treatment is a recurring bill. Tirzepatide’s median published figure across the sellers tracked here is $269 a month. The range runs 6.4 times, from $86 to $549.99, across 159 sellers. Set that beside what the whole market charges before a first order.

Dose matters to both halves. The 10 and 15 mg doses produced more weight loss than 5 mg, and sellers often publish nothing about what a higher dose costs. Over years, the gap between an advertised price and the billed one compounds. Price figures are computed from this site’s own records at build time, most recently read November 2026, across 183 priced sellers.

Frequently asked

How long can you safely take a GLP-1?
SELECT reported outcomes at 208 weeks in adults with established cardiovascular disease and no diabetes. The results describe that study population and cannot determine how long any individual should take the medication.
Do the side effects get worse over time?
Not in the long trials. In SURMOUNT-1, gastrointestinal events were mostly mild to moderate and occurred mainly in the first 20 weeks of dose escalation, with no new safety signals over three years.
Does the weight loss last if you stay on it?
In the trials, yes. SELECT measured −10.2% at 208 weeks on semaglutide, and SURMOUNT-1 measured −12.3% to −19.7% by dose at 176 weeks on tirzepatide.
What about thyroid cancer?
The label carries a boxed warning based on thyroid C-cell tumors in rodents. Whether semaglutide causes them in humans is unknown, and Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
What happens to the benefit if you stop?
In the SURMOUNT-1 group with obesity and prediabetes, diabetes had been diagnosed in 1.3% on tirzepatide and 13.3% on placebo at week 176. After 17 weeks off treatment, the figures were 2.4% and 13.7%.

Sources

  1. [1] Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. (2024). Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial Nature Medicine. PMID 38740993
  2. [2] Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial Nature Medicine. PMID 36216945
  3. [3] Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ (2024). Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials The American Journal of Cardiology. PMID 38679221
  4. [4] Jastreboff AM, et al. (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention New England Journal of Medicine. PMID 39536238
  5. [5] Novo Nordisk (2026). WEGOVY (semaglutide) — prescribing information DailyMed, U.S. National Library of Medicine. Source
  6. [6] U.S. Food and Drug Administration (2026). FDA Requires Safety Labeling Changes for GLP-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition FDA Drug Safety Communication, November 9, 2026. Source
  7. [7] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes New England Journal of Medicine. Source
  8. [8] Sisodia A, et al. (2026). Predicting GLP-1 Discontinuation From Pharmacy Claims The American Journal of Managed Care. PMID 42663544

More in Evidence